Scynexis (SCYX) Revenue (2013 - 2025)

Scynexis (SCYX) posted Revenue of $18.6 million for Q4 2025, up 5482.63% on a QoQ basis from $334000.0 in Q3 2025, and up 1808.5% year-over-year from $977000.0 in Q4 2024.

Scynexis (SCYX) Revenue (2013 - 2025) Analysis & Trends

Scynexis' Revenue history runs 12 years deep, the most recent figure standing at $18.6 million for Q4 2025.

  • Quarterly Revenue rose 1808.5% year-over-year to $18.6 million in Q4 2025, while the trailing twelve-month figure through Mar 2026 was $20.3 million (up 673.54% YoY) and the FY2025 annual result came in at $20.6 million, up 449.95% from the prior year.
  • Revenue was $18.6 million for Q4 2025 at Scynexis, up from $334000.0 in the prior quarter.
  • Across five years, Revenue topped out at $131.5 million in Q2 2023 and bottomed at $257000.0 in Q1 2025.
  • A 5-year average of $9.6 million and a median of $1.3 million in 2022 frame the typical range for Revenue.
  • Annual changes were most pronounced in 2023 — Revenue jumped 9836.05% — and 2024, when it plunged 99.44%.
  • Scynexis' Revenue stood at $597000.0 in 2021, then surged by 155.28% to $1.5 million in 2022, then surged by 280.38% to $5.8 million in 2023, then tumbled by 83.15% to $977000.0 in 2024, then soared by 1808.5% to $18.6 million in 2025.
  • Business Quant data shows SCYX's Revenue at $18.6 million in Q4 2025, $334000.0 in Q3 2025, and $1.4 million in Q2 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Revenue (Qtr)
1 Haleon 88.07 Bn 86.20 Bn - -
2 Teva Pharmaceutical Industries 35.75 Bn 32.01 Bn 1.97 Bn 3.98 Bn
3 Zoetis 31.84 Bn 29.90 Bn 1.62 Bn 2.26 Bn
4 Takeda Pharmaceutical 27.18 Bn 23.12 Bn 4.39 Bn 6.98 Bn
5 United Therapeutics 23.09 Bn 20.93 Bn 648.10 Mn 781.50 Mn
6 RedHill Biopharma 21.32 Bn 21.32 Bn - -
7 Viatris 19.96 Bn 18.16 Bn 1.16 Bn 3.51 Bn
8 Neurocrine Biosciences 17.66 Bn 16.34 Bn 800.70 Mn 814.50 Mn
9 Elanco Animal Health 12.44 Bn 12.02 Bn 785.00 Mn 1.37 Bn
10 Scynexis 24.46 Mn -12.29 Mn - -

Historic Data

Download Data
DateValue
Dec 31, 2025 18.65 Mn
Sep 30, 2025 334,000.00
Jun 30, 2025 1.36 Mn
Mar 31, 2025 257,000.00
Dec 31, 2024 977,000.00
Sep 30, 2024 660,000.00
Jun 30, 2024 736,000.00
Mar 31, 2024 1.37 Mn
Dec 31, 2023 5.80 Mn
Sep 30, 2023 1.76 Mn
Jun 30, 2023 131.45 Mn
Mar 31, 2023 1.13 Mn
Dec 31, 2022 1.52 Mn
Sep 30, 2022 1.56 Mn
Jun 30, 2022 1.32 Mn
Mar 31, 2022 700,000.00
Dec 31, 2021 597,000.00
Sep 30, 2021 516,000.00
Mar 31, 2021 12.05 Mn
Jun 30, 2019 57,000.00